SCHEMBL2867346

SCHEMBL2867346

O=S(=O)(NC(Cc1ccccc1)C1CCCCC1)c1ccccc1OC(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 1/20 0.40
CNR2 P34972 2/20 0.39
RORC P51449 1/20 0.39
ALPL P05186 1/20 0.39
CASP1 P29466 2/20 0.38
SLC22A12 Q96S37 3/20 0.38
SLC40A1 Q9NP59 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 1/20 0.38
KCNA5 P22460 1/20 0.38
NSD2 O96028 1/20 0.38
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MME P08473 1/20 0.37
F2 P00734 1/20 0.37
GSPT1 P15170 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864239 0.77 USP30 (0.46) ADRB3CYP3A4CYP2C19POLB
SCHEMBL2853532 0.75 ALDH1A1 (0.58) CYP3A4CYP2C19MAPTSMN1; SMN2
SCHEMBL4433353 0.73 ALDH1A1 (0.52) ALPLSLC22A12SLC40A1MAPTSMN1; SMN2
SCHEMBL14718102 0.72 SLC22A12 (0.43) CNR2RORCALPLCASP1SLC22A12
SCHEMBL14718098 0.72 SLC22A12 (0.43) CNR2RORCALPLCASP1SLC22A12
SCHEMBL14718097 0.72 SLC22A12 (0.43) CNR2RORCALPLCASP1SLC22A12
SCHEMBL14718100 0.72 SLC22A12 (0.43) CNR2RORCALPLCASP1SLC22A12
SCHEMBL12491364 0.72 SMN1; SMN2 (0.54) ALPLSLC22A12SLC40A1CYP2C19NSD2
SCHEMBL10154346 0.69 ALPL (0.52) CNR2ALPLSLC22A12SLC40A1MAPT
SCHEMBL2867340 0.69 CCR1 (0.43) CNR2RORCALPLSLC22A12SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed